great
interest
develop
abinduc
subunit
vaccin
target
infect
includ
hiv
malaria
ebola
previous
report
adenoviru
vector
vaccin
potent
prime
ab
respons
uncertainti
remain
regard
optim
approach
induct
humor
immun
respons
studi
use
ova
model
ag
assess
magnitud
primari
anamnest
agspecif
igg
respons
mice
four
clinic
relev
vaccin
formul
replicationdefici
adenoviru
modifi
vaccinia
ankara
poxviru
protein
alum
protein
squalen
oilinwat
adjuv
addavax
use
flow
cytometr
assay
capabl
measur
total
agspecif
germin
center
gc
b
cell
follicular
th
cell
respons
compar
induct
respons
differ
formul
report
adenoviru
vector
vaccin
induc
ag
insertspecif
gc
b
cell
ab
respons
magnitud
compar
induc
potent
proteinsqualen
oilinwat
formul
whereasdespit
robust
overal
gc
responseth
insertspecif
gc
b
cell
ab
respons
induc
modifi
vaccinia
ankara
extrem
weak
agspecif
follicular
th
cell
respons
adenoviru
vector
vaccin
exceed
induc
platform
day
immun
found
littl
evid
innat
immun
activ
adenoviru
may
act
adjuv
manner
humor
respons
recombin
protein
may
enhanc
coadminist
adenoviru
lack
transgen
interest
overal
studi
provid
support
use
replicationdefici
adenovirus
induc
humor
respons
great
interest
develop
abinduc
subunit
vaccin
target
infect
includ
hiv
malaria
ebola
previous
report
adenoviru
vector
vaccin
potent
prime
ab
respons
uncertainti
remain
regard
optim
approach
induct
humor
immun
respons
studi
use
ova
model
ag
assess
magnitud
primari
anamnest
agspecif
igg
respons
mice
four
clinic
relev
vaccin
formul
replicationdefici
adenoviru
modifi
vaccinia
ankara
poxviru
protein
alum
protein
squalen
oilinwat
adjuv
addavax
use
flow
cytometr
assay
capabl
measur
total
agspecif
germin
center
gc
b
cell
follicular
th
cell
respons
compar
induct
respons
differ
formul
report
adenoviru
vector
vaccin
induc
ag
insertspecif
gc
b
cell
ab
respons
magnitud
compar
induc
potent
proteinsqualen
oilinwat
formul
whereasdespit
robust
overal
gc
responseth
insertspecif
gc
b
cell
ab
respons
induc
modifi
vaccinia
ankara
extrem
weak
agspecif
follicular
th
cell
respons
adenoviru
vector
vaccin
exceed
induc
platform
day
immun
found
littl
evid
innat
immun
activ
adenoviru
may
act
adjuv
manner
humor
respons
recombin
protein
may
enhanc
coadminist
adenoviru
lack
transgen
interest
overal
studi
provid
support
use
replicationdefici
adenovirus
induc
humor
respons
journal
immunolog
f
mani
infectionsnot
malaria
hiv
also
numer
diseas
human
livestockth
induct
ab
respons
recombin
subunit
vaccin
lead
approach
develop
efficaci
vaccin
advantag
subunit
vaccin
approach
liveattenu
kill
vaccin
includ
abil
focu
immun
respons
upon
tailormad
immunogen
exampl
design
elicit
respons
neutral
conserv
epitop
therefor
intens
interest
develop
subunit
vaccin
approach
optim
humor
immunogen
area
particular
interest
includ
optim
peak
ab
titer
recal
respons
ag
somat
hypermut
longterm
mainten
ab
respons
meet
requir
numer
vaccin
deliveri
platform
investig
consider
array
immunostimul
adjuv
approach
suitabl
formul
recombin
protein
ag
reach
variou
stage
clinic
preclin
develop
parallel
extens
effort
made
develop
replicationdefici
viral
vector
vaccin
platform
capabl
deliv
ag
encod
transgen
although
origin
develop
primarili
capac
induc
strong
cellular
immun
responsesparticularli
ctl
responsesther
recent
consider
interest
capac
viral
vector
vaccin
induc
potent
humor
respons
previou
data
studi
conduct
group
mice
rhesu
macaqu
human
suggest
particular
advantag
regim
replicationdefici
adenoviru
use
prime
vaccin
follow
boost
vaccin
deliv
ag
differ
manner
either
proteinadjuv
heterolog
viral
vector
modifi
vaccinia
ankara
mva
regim
use
adenovir
prime
appear
overcom
need
formul
boost
immunogen
potent
adjuv
reach
high
postboost
ab
titer
word
regim
use
adenoviru
prime
follow
boost
use
recombin
protein
adjuv
convent
regard
rel
weak
capabl
induc
ab
titer
match
induc
potent
proteinadjuv
regim
studi
address
mechan
effect
achiev
although
detail
studi
process
viral
vector
vaccin
induc
cell
respons
rel
littl
explor
process
vaccin
induc
humor
respons
dramat
differ
transgen
ag
express
kinet
demonstr
immun
replicationdefici
adenoviru
poxviru
vector
former
achiev
high
level
ag
express
wherea
mva
induc
brief
highlevel
burst
ag
express
appear
benefici
ctl
induct
may
achiev
suffici
level
free
ag
optim
humor
respons
eleg
studi
delin
number
pathway
innat
immun
activ
contribut
immunogen
adenoviru
vector
role
plasmacytoid
dendrit
cell
activ
nfkb
activ
tlrindepend
activ
type
ifn
drive
signal
b
cell
germin
center
gc
agspecif
b
cell
receiv
help
cognat
follicular
helper
tfh
cell
central
humor
immun
respons
princip
site
somat
hypermut
main
sourc
memori
b
cell
longliv
plasma
cell
respons
tdepend
protein
ag
knowledg
littl
data
compar
viral
vector
vaccin
versu
proteinadjuv
vaccin
abil
induc
gc
b
cell
tfh
respons
comparison
hinder
fact
contrast
proteinonli
immun
proport
total
immun
respons
viral
vector
vaccin
direct
structur
compon
vector
rather
toward
desir
target
ag
express
insert
transgen
studi
made
use
flow
cytometr
assay
design
identifi
agspecif
gc
b
cell
tfh
cell
compar
induct
cell
popul
varieti
viral
vector
proteinadjuv
vaccin
platform
extend
studi
investig
possibl
given
known
abil
adenoviru
activ
innat
immun
nonantigen
encod
adenoviru
could
act
adjuv
coadminist
solubl
protein
word
ag
adenoviru
need
administ
ci
could
administ
tran
show
fact
littl
tran
adjuv
effect
ab
gc
tfh
induct
appear
abil
adenoviru
induc
robust
humor
respons
depend
express
ag
within
cell
infect
adenoviru
state
result
comprehens
comparison
viral
vector
vaccin
proteininadjuv
formul
clearli
imposs
select
appropri
vector
adjuv
dose
requir
complic
difficulti
extrapol
dose
use
mice
suitabl
use
human
follow
section
set
rational
choic
vaccin
platform
compar
studi
dose
use
humor
respons
vaccin
gener
rise
increas
ag
dose
littl
evid
higher
dose
deleteri
platform
wish
studi
therefor
select
dose
upper
end
rang
dose
suitabl
use
mice
obtain
optim
respons
adenoviru
probabl
lead
viral
vector
platform
ab
respons
induct
reach
clinic
trial
varieti
major
diseas
attract
interest
lead
pharmaceut
compani
repres
approach
use
human
adenoviru
serotyp
express
model
ag
ova
wide
studi
adenoviru
vaccin
vector
although
use
human
limit
preval
neutral
ab
among
immunogen
adenovector
mice
primat
varieti
differ
within
adenoviru
speci
member
adenoviru
speci
c
similar
sequenc
level
term
immunogen
clinic
use
adenoviru
serotyp
human
adenoviru
serotyp
throughout
use
dose
infecti
unit
human
adenoviru
serotyp
express
ova
viru
prepar
use
correspond
viru
particl
upper
end
rang
adenoviru
dose
use
mous
studi
group
investig
highest
adenovirusvector
vaccin
dose
awar
use
human
typic
human
dose
poxviru
vector
also
employ
vaccin
vector
aim
ab
induct
includ
clinic
trial
vacciniabas
licens
veterinari
vaccin
rabi
studi
select
mva
repres
group
replicationdefici
poxvirus
develop
human
vaccin
mva
among
studi
poxviru
vector
transgeneag
immunogen
favor
compar
poxvirus
mva
dose
pfu
also
upper
end
rang
dose
use
previous
publish
mous
studi
highest
dose
awar
use
human
typic
human
dose
although
limit
number
exampl
mva
dose
pfu
use
mice
publish
data
suggest
pfu
suffici
achiev
optim
humor
respons
deliv
im
rout
oppos
suboptim
sc
clinic
less
relev
ip
rout
mva
use
express
gfp
marker
previous
produc
gfpexpress
markerless
version
sever
mva
virus
observ
detect
differ
ag
transgen
immunogen
data
shown
protein
dose
use
mous
immun
literatur
vari
sever
order
magnitud
studi
select
dose
mg
ova
invivogen
toward
upper
end
typic
use
rang
adjuv
protein
vaccin
first
select
alum
wide
use
adjuv
current
licens
vaccin
al
oh
base
alum
adjuv
alhydrogel
invivogen
chosen
prefer
aluminum
phosphat
previou
data
demonstr
superior
immunogen
former
presum
adsorpt
neg
charg
ova
protein
posit
charg
al
oh
mg
al
given
per
dose
consist
previou
work
second
clinic
plausibl
adjuv
select
squalen
oilinwat
ow
emuls
addavax
invivogen
dose
accord
manufactur
recommend
proprietari
similar
squalen
ow
formul
novarti
gsk
among
rel
novel
adjuv
formul
current
use
licens
vaccin
demonstr
ag
express
mvaova
vector
detect
ova
express
western
blot
supernat
infect
cell
cultur
cell
cultur
rpmi
medium
fc
infect
either
express
irrelev
malaria
ag
multipl
infect
infecti
unitscel
bhk
cell
cultur
similarli
infect
either
mvaova
multipl
infect
pfucel
cell
supernat
infect
cell
collect
separ
h
postinfect
boil
xt
reduc
agent
laemlli
buffer
biorad
run
novex
nupag
bistri
sd
gel
thermofish
transfer
nitrocellulos
membran
use
transblot
turbo
system
biorad
blot
use
ibind
system
thermofish
serum
mice
immun
ova
protein
use
primari
ab
detect
use
alkalinephosphataseconjug
donkeyantimous
igg
jackson
laboratori
bcipnbt
sigmaaldrich
recombin
ova
invivogen
use
posit
control
anim
work
approv
univers
oxford
anim
welfar
ethic
review
bodi
review
applic
uk
home
offic
project
licens
ppl
femal
mice
harlan
hous
specificpathogenfre
facil
wk
old
initi
experi
product
mvaova
vaccin
report
elsewher
brief
ova
transgen
includ
human
tissu
plasminogen
activ
signal
sequenc
fulllength
chicken
ova
sequenc
amino
acid
substitut
substitut
previous
report
prevent
nlink
glycosyl
residu
result
express
mammalian
cell
protein
pattern
glycosyl
match
hen
egg
ova
vector
transgen
driven
introncontain
cmv
immediateearli
promot
promot
close
relat
variant
use
major
adenovirus
enter
clinic
trial
empti
includ
transgen
promot
polya
tail
agcod
sequenc
adenovir
vaccin
grown
trex
cell
life
technolog
purifi
cscl
centrifug
titer
uv
spectrophotometri
measur
viral
particl
per
millilit
hexon
immunostain
assess
infecti
unit
per
millilit
particl
infecti
unit
ratio
mvaova
vector
transgen
driven
promot
insert
thymidin
kinas
locu
wide
use
promot
recombin
poxviru
vaccin
vector
mva
vaccin
grown
chicken
embryo
fibroblast
purifi
centrifug
sucros
cushion
titer
fluoresc
plaqu
assay
use
gfp
marker
measur
pfu
per
millilit
endotoxinfre
chicken
ova
adjuv
purchas
invivogen
endofit
ova
addavax
alhydrogel
colloid
suspens
aluminum
hydroxid
dose
use
infecti
unit
pfu
mva
mg
ova
protein
ml
addavax
mg
al
form
al
oh
rational
select
dose
explain
proteinadjuv
formul
prepar
accord
manufactur
recommend
vaccin
dilut
pb
total
volum
ml
administ
im
split
equal
gastrocnemiu
muscl
hind
limb
elisa
elisa
perform
essenti
describ
previous
brief
plate
coat
ova
protein
invivogen
endofit
mlwell
mgml
dilut
test
sera
triplic
standard
curv
produc
use
serial
dilut
refer
serum
pool
ovaimmun
mice
ad
plate
wash
secondari
ab
bind
final
wash
detect
previous
describ
except
secondari
ab
use
alkalinephosphataseconjug
goat
antimous
igg
sigmaaldrich
od
quantifi
use
plate
reader
biotek
result
express
ab
unit
au
defin
use
refer
standard
interpol
od
read
standard
curv
inguin
lymph
node
harvest
immers
optimum
cut
temperatur
oct
compound
vwr
chemic
immedi
frozen
dri
ice
thirtyfivemicromet
section
cut
use
cryostat
leica
mount
superfrost
ultra
plu
slide
thermo
scientif
gerhard
menzel
fix
aceton
min
airdri
min
store
prior
stain
nonspecif
ab
bind
block
use
solut
vv
normal
mous
serum
wv
bsa
sigmaaldrich
vv
triton
sigmaaldrich
primari
ab
secondari
reagent
use
detail
supplement
tabl
final
wash
fluoromount
g
mount
medium
ebiosci
appli
follow
coverslip
slide
visual
use
zeiss
lsm
confoc
microscop
imag
acquir
use
zen
softwar
zeiss
imagej
nation
institut
health
use
imag
process
imag
analyz
manner
allow
comparison
overal
gc
area
proport
b
cell
area
occupi
gc
gc
b
cell
area
identifi
use
stain
respect
manual
defin
area
calcul
poplit
inguin
paraaort
lymph
node
note
enlarg
respons
immun
therefor
togeth
consid
relev
drain
lymph
node
dln
harvest
store
ice
rpmi
medium
h
prepar
singlecel
suspens
stain
reagent
use
set
supplement
tabl
chosen
gc
b
cell
marker
mhc
class
ii
mhcii
tetram
compris
peptid
display
ia
b
tetramer
pelabel
streptavidin
sape
obtain
nih
tetram
core
facil
emori
univers
stain
ovareact
cell
mixtur
prepar
compris
tetram
display
peptid
tewtssnvmeerkikv
ova
residu
aahaeinea
ova
residu
haahaeinea
ova
residu
prepar
b
cell
tetram
cell
transient
cotransfect
plasmid
encod
bira
biotin
ligas
ova
ctermin
biotin
acceptor
peptid
ctag
peptid
epea
follow
express
purif
protein
perform
use
captureselect
ctag
resin
life
technolog
purifi
protein
extens
dialyz
incub
sape
life
technolog
residu
unreact
sape
ova
remov
size
exclus
chromatographi
use
superdex
column
ge
prior
use
reagent
confirm
stain
bead
coat
antiova
mous
serum
case
b
cell
stain
singlestep
surfac
viabil
stain
carri
pb
preced
block
fcmediat
ab
bind
ebiosci
rpmi
medium
heatinactiv
fc
medium
case
tfh
stain
cell
incub
h
class
ii
tetram
subsequ
surfac
viabil
stain
pb
sampl
acquir
lsrii
flow
cytomet
bd
bioscienc
analyz
use
flowjo
softwar
tree
star
ovareact
b
cell
defin
use
fulli
stain
cell
mice
vaccin
set
gate
exclud
gc
b
cell
mice
addit
neg
control
gate
confirm
exclud
igd
b
cell
vaccin
mice
program
cell
death
protein
cell
defin
use
fluoresc
minu
one
control
ovamhcii
cell
defin
use
fulli
stain
cell
naiv
mice
vaccin
set
gate
exclud
cell
mice
addit
neg
control
cell
stain
tetram
display
irrelev
peptid
pvskmrmatpllmqa
human
clip
residu
prism
softwar
graphpad
use
product
figur
statist
analys
statist
method
use
analysi
set
detail
appropri
figur
legend
cell
count
ab
titer
data
log
transform
prior
analysi
given
plethora
avail
platform
dose
regim
comprehens
comparison
vector
proteinadjuv
vaccin
possibl
degre
select
clearli
requir
challeng
perform
comparison
aris
uncertainti
regard
compar
doserespons
relationship
differ
platform
mice
human
use
dose
infecti
unit
mvaova
dose
pfu
ova
protein
dose
mg
aluminum
hydroxid
dose
mg
al
addavax
dose
ml
rational
choic
platform
dose
set
detail
materi
method
vitro
ova
express
mvaova
vector
confirm
western
blot
shown
supplement
fig
select
vaccin
platform
dose
proceed
compar
abil
platform
induc
primari
agspecif
ab
respons
fig
recal
respons
upon
reencount
standard
ag
challeng
use
proteinalum
boost
vaccin
formul
mice
fig
consist
previou
data
agspecif
ab
respons
prime
close
compar
prime
ova
protein
potent
adjuv
addavax
signific
differ
either
boost
vaccin
ova
alum
consist
previou
experi
respons
prime
trend
slightli
higher
induc
ova
alum
prime
reach
significantli
higher
level
boost
also
small
nonetheless
statist
signific
differ
respons
elicit
prime
ova
addavax
versu
ova
alum
former
elicit
higher
respons
boost
vaccin
contrast
respons
observ
mva
rel
weak
prime
agent
elicit
neither
strong
primari
ab
respons
strong
recal
respons
upon
subsequ
encount
protein
ag
explor
reason
potenc
ab
induct
adenoviru
weak
respons
elicit
mva
sought
explor
gc
respons
viral
vector
compar
proteininadjuv
formul
initi
visual
overal
gc
respons
use
immunofluoresc
stain
tissu
section
collect
day
immun
typic
close
time
peak
respons
vaccin
observ
vigor
induct
gc
mva
significantli
weaker
respons
proteininaddavax
wherea
respons
protein
alum
slightli
weaker
fig
thu
discrep
overal
magnitud
gc
respons
induc
rel
abil
differ
platform
induc
ova
agspecif
primari
recal
ab
respons
particularli
respect
comparison
adenoviru
mva
vector
fig
hypothes
discrep
like
due
portion
overal
gc
respons
viral
vector
immun
direct
toward
vector
focu
ag
insertspecif
respons
vector
immun
develop
flow
cytometr
stain
panel
capabl
detect
ovaspecif
gc
b
cell
tfh
cell
fig
pregat
total
gc
b
cell
defin
igd
fig
initi
found
unabl
discern
agspecif
gc
b
cell
use
either
monomer
ova
label
fluorophor
life
technolog
inhous
b
cell
tetram
produc
chemic
biotinyl
ova
follow
incub
streptavidin
data
shown
subsequ
develop
b
cell
tetram
use
ova
enzymat
monobiotinyl
c
terminu
tetram
stain
proport
gc
b
cell
mice
vaccin
ovaexpress
adenoviru
mice
receiv
empti
adenoviru
fig
sitespecif
biotinyl
approach
similar
use
gener
mhc
tetram
presum
produc
homogen
popul
tetram
chemic
biotinyl
nearrandom
site
approach
simpl
readili
transfer
ag
may
therefor
use
investig
seek
identifi
agspecif
b
cell
increas
appreci
field
import
role
tfh
cell
orchestr
b
cell
respons
therefor
sought
quantifi
agspecif
tfh
respons
induc
variou
platform
opt
use
mhcii
ova
peptid
streptavidinfluorophor
tetram
detect
ovaspecif
tfh
cell
wildtyp
mice
tetram
stain
proport
tfh
cell
defin
cell
mice
vaccin
ovaexpress
adenoviru
mice
receiv
empti
adenoviru
fig
approach
avoid
possibl
spuriou
result
aris
transfer
transgen
ovaspecif
cell
otii
may
produc
unnatur
frequenc
agspecif
cell
although
gc
respons
typic
peak
around
ten
day
primari
immun
solubl
protein
ag
express
ag
adenoviru
vector
peak
around
immun
persist
wk
therefor
consid
possibl
kinet
respons
adenovirus
might
differ
respons
solubl
protein
ensur
subsequ
comparison
vector
proteinimmun
anim
use
tissu
collect
singl
time
point
would
valid
sought
initi
compar
kinet
respons
adenoviru
proteinaddavax
immun
anim
fig
lymph
node
enlarg
reflect
elev
total
dln
lymphocyt
count
appar
day
adenoviru
proteinadjuv
immun
fig
observ
total
gc
b
cell
ova
agspecif
gc
b
cell
respons
peak
day
vector
proteinadjuv
immun
anim
fig
although
main
focu
studi
earli
period
peak
gc
show
gate
tfh
cell
defin
pregat
live
singlet
lymphocyt
agspecif
tfh
cell
identifi
bind
ova
peptideclass
ii
tetram
gate
threshold
set
refer
tfh
cell
naiv
mice
mice
vaccin
nonovaexpress
adenoviru
e
show
mhciiova
tetram
bind
tfh
cell
mous
vaccin
f
show
lack
mhciiova
tetram
bind
tfh
cell
naiv
mous
control
includ
assess
bind
control
tetram
ia
b
human
clip
tfh
cell
ovavaccin
mice
neglig
assess
use
gate
threshold
data
shown
respons
notabl
substanti
ag
insertspecif
gc
b
respons
remain
detect
day
immun
adenoviru
wherea
respons
proteinadjuv
vaccin
markedli
contract
time
fig
persist
gc
respons
may
import
exampl
permit
optim
memori
b
cell
gener
somat
hypermut
broadli
speak
time
tfh
respons
similar
gc
b
cell
respons
tfh
respons
howev
expand
somewhat
rapidli
immun
adenoviru
proteinaddavax
peak
around
day
former
compar
around
day
latter
fig
ovaspecif
tfh
cell
bare
detect
day
immun
either
platform
previous
report
agspecif
plasma
cell
respons
bone
marrow
late
time
point
vaccin
viral
vector
studi
briefli
examin
earli
plasma
cell
respons
drain
lymph
node
larg
number
plasma
cell
present
within
vaccin
adenoviru
kinet
differ
substanti
gc
b
cell
supplement
fig
although
tempt
specul
magnitud
respons
compar
proteinadjuv
respons
assay
use
detect
cell
capabl
discrimin
ovaspecif
adenoviru
vectorspecif
plasma
cell
defin
kinet
respons
proceed
use
flow
cytometri
assay
compar
detail
magnitud
gc
b
tfh
cell
respons
induc
differ
vaccin
platform
around
peak
time
point
fig
assumpt
made
peak
time
point
respons
mva
proteinalum
immun
would
similar
adenoviru
proteinaddavax
immun
profil
overal
gc
b
cell
tfh
induct
expect
larg
parallel
size
gc
visual
immunofluoresc
immun
platform
fig
wherea
margin
total
gc
b
cell
respons
appar
addavax
alum
given
without
ag
magnitud
respons
adenoviru
lack
insert
ag
transgen
close
similar
induc
ovaexpress
adenoviru
fig
differ
pattern
appar
examin
ag
insertspecif
b
cell
although
adenoviru
result
greater
popul
total
gc
b
cell
ovaspecif
gc
b
cell
proteinadjuv
vaccin
mva
induc
ovaspecif
gc
b
cell
despit
abil
induc
vigor
overal
respons
fig
high
ratio
noninsertspecif
ag
insertspecif
gc
b
cell
mva
immun
may
reflect
antigen
complex
larg
mva
virion
total
tfh
respons
viral
vector
platform
greater
proteininadjuv
vaccin
fig
platform
proport
total
tfh
cell
detect
bound
mhcii
tetram
typic
nonetheless
agspecif
tfh
respons
clearli
detect
background
level
ovaspecif
tfh
respons
significantli
higher
adenovirusvaccin
mice
group
fig
differ
longer
appar
day
consist
find
kinet
analysi
suggest
time
point
tfh
respons
proteinadjuv
immun
mice
reach
peak
respons
adenovirusimmun
mice
begun
declin
data
shown
ovaspecif
tfh
respons
mva
compar
favor
induc
proteininadjuv
formul
suggest
poor
agspecif
gc
b
cell
igg
respons
elicit
mva
vector
probabl
attribut
limit
tfh
frequenc
abil
adenoviru
induc
robust
adapt
immun
respons
appear
depend
innat
immun
activ
unclear
whether
ag
need
express
cell
experienc
virustrigg
innat
activ
ag
ci
whether
degre
spatiotempor
linkag
protein
ag
viru
necessari
might
suffici
loos
permit
nontransgeneexpress
empti
adenoviru
adjuv
immunogen
coadminist
recombin
protein
ag
tran
fig
show
fact
littl
effect
coadminist
empti
adenoviru
upon
ab
cellular
respons
statist
signific
differ
igg
respons
unadjuv
ova
protein
ova
protein
mix
empti
adenoviru
preboost
postboost
timepoint
fig
p
twotail
test
total
gc
b
cell
total
tfh
cell
respons
mixtur
ova
protein
empti
adenoviru
compar
respons
empti
adenoviru
alon
fig
ovaspecif
gc
b
cell
tfh
cell
respons
proteinempti
adenoviru
mixtur
bare
detect
fig
particularli
case
ovaspecif
gc
b
cell
respons
consider
lower
respons
comparison
properti
differ
vaccin
platform
challeng
task
necessari
guid
develop
priorit
novel
approach
agplatform
combin
assess
undertaken
human
preclin
assess
carri
benefit
access
tissu
reach
human
expens
number
drawback
includ
uncertainti
regard
compar
anim
dose
safe
toler
human
dose
studi
sought
compar
humor
respons
two
viral
vector
two
proteinadjuv
vaccin
platform
mice
use
fulllength
structur
protein
ag
oppos
hapten
clinic
relev
im
rout
immun
focus
assess
igg
respons
gc
respons
primari
immun
chose
use
assay
capabl
detect
agspecif
gc
b
cell
tfh
cell
respons
wildtyp
mice
prefer
artifici
system
use
transgen
cell
given
rariti
mhcii
tetramerbind
tfh
cell
made
challeng
quantifi
respons
experi
would
clearli
interest
replic
experi
use
adopt
transfer
transgen
cell
nonetheless
clear
respons
detect
condit
use
assay
current
contrast
increas
interest
develop
adenoviru
vector
ab
induct
notabl
respons
recent
ebola
epidem
persist
belief
quarter
viral
vector
second
best
option
ab
induct
inferior
proteinadjuv
vaccin
current
data
provid
support
notion
adenoviru
vector
potent
induc
b
cell
respons
induc
igg
respons
also
gc
b
cell
tfh
cell
respons
compar
favor
induc
lead
clinic
relev
proteinadjuv
formul
observ
potent
agspecif
gc
b
cell
respons
adenovirus
goe
way
toward
explain
previou
data
suggest
prime
immun
recombin
adenoviru
overcom
requir
inclus
potent
adjuv
protein
boost
reach
optim
postboost
ab
titer
robust
gc
respons
adenovirusdeliv
transgen
like
result
substanti
expand
agspecif
memori
b
cell
pool
magnitud
adenovirusinduc
memori
b
cell
respons
extent
somat
hypermutationboth
larg
gcdepend
processeswil
clearli
worthwhil
topic
futur
investig
data
underscor
import
assess
agspecif
rather
total
gc
respons
compar
viral
vector
proteinadjuv
formul
unsurprisingli
adenoviru
mva
dose
infecti
unit
pfu
respect
induc
larger
popul
noninsertspecif
gc
b
cell
proteinadjuv
vaccin
case
mva
noninsertspecif
respons
domin
extent
margin
gc
b
cell
respons
detect
insert
vaccin
ag
possibl
explan
might
includ
high
ratio
viral
transgen
protein
express
transienc
ag
express
mva
immun
induct
dendrit
cell
apoptosi
mva
although
observ
abil
vaccinia
achiev
abmedi
protect
smallpox
encourag
use
poxviru
vector
vaccin
ab
induct
caution
clearli
requir
regard
abil
induc
respons
solubl
secret
insert
ag
agnaiv
anim
situat
agexperienc
anim
avail
agspecif
b
cell
pool
larger
like
differ
context
agspecif
b
cell
respons
poxviru
vaccin
may
well
constitut
consider
greater
proport
total
respons
viral
vector
better
known
abil
induc
cell
respons
induct
ab
other
previous
specul
induct
tfh
cell
viral
vector
could
superior
proteinadjuv
formul
could
partli
explain
robust
abil
adenovirus
prime
humor
respons
overal
magnitud
tfh
respons
measur
studi
correl
fairli
poorli
ab
immunogen
measur
elisa
although
ovaspecif
tfh
respons
day
vaccin
adenoviru
significantli
higher
induc
platform
consist
good
ab
induct
adenoviru
tfh
respons
mva
trend
higher
proteininadjuv
formul
yet
humor
immunogen
mva
extrem
poor
clearli
scope
studi
area
notabl
compar
analysi
function
attribut
tfh
respons
elicit
differ
regim
would
interest
may
differ
bia
cell
respons
elicit
result
qualit
differ
tfh
respons
relationship
measur
respons
dln
humor
respons
imperfect
ab
induct
adova
similar
proteinaddavax
despit
superior
ovaspecif
gc
b
tfh
respons
convers
ab
induct
protein
addavax
superior
proteinalum
despit
similar
level
agspecif
gc
b
tfh
cell
seem
like
condit
certain
level
gc
b
tfh
respons
reach
addit
unmeasur
factor
becom
limit
upon
igg
respons
final
result
suggest
littl
effect
noninsertexpress
adenoviru
upon
humor
respons
coadminist
protein
ag
spatiotempor
associ
adjuvantinduc
innat
immun
signal
ag
avail
shown
critic
immunogen
vaccin
platform
although
result
prove
ag
need
express
cell
infect
adenoviru
vector
suggest
spatiotempor
linkag
coadminist
protein
adenoviru
insuffici
tight
achiev
adjuvant
overal
result
provid
encourag
use
adenoviralvector
vaccin
ab
induct
clinic
trial
data
other
demonstr
platform
capabl
robust
humor
immunogen
human
ultim
appropri
choic
vaccin
platform
given
diseas
target
becom
increasingli
nuanc
diseas
requir
induct
ab
respons
agnaiv
subject
protein
difficult
produc
conform
accuraci
vitronot
mani
viral
glycoprotein
eukaryot
parasit
agsadenovirus
increasingli
attract
choic
